Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients
Reason given: Funding was withdrawn
Key facts
- Where
- New York, United StatesSee the 4 sites
Where in United States
- Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer CenterNew York, United StatesNo longer taking part
- Montefiore Health CenterNew York, United StatesNo longer taking part
- Mount Sinai School of MedicineNew York, United StatesNo longer taking part
- NYU Medical CenterNew York, United StatesNo longer taking part
Trial details
- Who runs it
- Columbia University
- Trial code
- NCT05812274
- Record updated
- 5 May 2026
- Original description
The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.Read full original descriptionShow less
A Phase IV Study of Apricity C.A.R.E. Program for Cancer Adverse Events Rapid Evaluation to Improve Treatment Outcomes of Ethnic/Racial Minority Non-small Cell Lung Cancer (NSCLC) Patients Receiving Immunotherapy
The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.
Inclusion: Age≥ 18 years; Confirmed NSCLC diagnosis; Prescribed treatment with immune-checkpoint inhibitor, including in combination with chemotherapy; Ability to understand and the willingness to sign a written informed consent document; Self-identification as a member of an ethnic minority or underserved population.
Exclusion: An individual with presence of any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study; Patients enrolled in other interventional clinical trials at the time of screening will be excluded.